ANI Pharmaceuticals Profile

58.04
USD 0.64  1.09%
21%
30%

Exercise or conversion by Arthur Przybyl of 15723 shares of ANI Pharmaceuticals subject to Rule 16b-3

ANI Pharmaceuticals insider trading alert for exercise of stock option by Arthur Przybyl, President and CEO, on April 21, 2018. This event was filed by Ani Pharmaceuticals Inc with SEC on 2018-03-14. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

ANI Pharmaceuticals Summary

ANI Pharmaceuticals (ANIP) is traded on NASDAQ General Markets in USA. It is located in MINNESOTA, U.S.A and employs 173 people. ANI Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Small-Cap' category with current market capitalization of 688.19 M. ANI Pharmaceuticals conducts business under Healthcare sector and is part of Biotechnology industry. This company has 11.73 M outstanding shares of which 882.69 K shares are presently shorted by private and institutional investors with about 6.07 trading days to cover. ANI Pharmaceutica currently holds about 31.14 M in cash with 39.42 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.67.
Check ANI Pharmaceuticals Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Below OddsHorizonTargetAbove Odds
about 15.95%30 days 58.04  about 83.85%
Based on normal probability distribution, the odds of ANI Pharmaceuticals to move above current price in 30 days from now is about 83.85% (This ANI Pharmaceuticals probability density function shows the probability of ANI Pharmaceuticals Stock to fall within a particular range of prices over 30 days) .

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
First Manhattan CoCommon Shares145.7 K8.5 M
Regent Investment Management LlcCommon Shares36 K2.1 M
Creative PlanningDebt28 K31 K
View ANI Pharmaceuticals Diagnostics

Selected ANI Pharmaceuticals Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Gross Profit    

Key Fundamentals

ANI Pharmaceuticals Against Markets

Risk Adjusted
Performance Score (0 to 100)
2 
Chance of
Financial Distress (0 to 100%)
< 43% 
Equity ratings for ANI Pharmaceuticals are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. ANI Pharmaceuticals, Inc. is headquartered in Baudette, Minnesota. ANI Pharmaceuticals operates under Biotechnology classification in USA and traded on NASDAQ General Markets. It employs 173 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameANI Pharmaceuticals
CEO and President and DirectorArthur PrzybylView All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock View All
RegionNorth America
LocationMINNESOTA, U.S.A
Business Address210 Main Street West
ExchangeNASDAQ General Markets
CIK Number01023024.0
CUSIP00182C103
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.anipharmaceuticals.com
Contact Number218 634 3500
Related EntityBPA
CurrencyUSD - US Dollar

Recommendations

ANI Pharmaceuticals Analyst Recommendations
Target PriceAdvice# of Analysts
71.0Buy2Odds
ANI Pharmaceuticals current and past analyst recommendations published by number of research institutions as well as average analyst consensus
ANI Pharmaceuticals Analyst Advice  

Earnings

ANI Pharmaceuticals Earnings Estimates
EPSEstimate Date
Quarterly Estimate1.02March 2, 2017
ANI Pharmaceuticals normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  

Directors

ANI Pharmaceuticals Corporate Directors
Daniel Raynor Director
Peter Lankau Director
Fred Holubow Independent Director
Check also Trending Equities. Please also try Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.